Abstract: An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level.

Abstract: A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency. The invention provides a method for producing induced pluripotent stem cells comprising the step of introducing one or more nucleic acids that facilitate expression of at least one gene selected from the group consisting of NANOG, SOX2, OCT3/4, KLF4, LIN28, and c-MYC into somatic cells.

Abstract: An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level.

Abstract: A major object of the present invention is to provide a method for producing induced pluripotent stem cells with low tumorigenesis potential and high induction efficiency. The invention provides a method for producing induced pluripotent stem cells comprising the step of introducing one or more nucleic acids that facilitate expression of at least one gene selected from the group consisting of NANOG, SOX2, OCT3/4, KLF4, LIN28, and c-MYC into somatic cells.

Abstract: The invention refers to a method of treating medical conditions through the application of solar energy stored papers during sunrise or sunset comprising the steps of storing solar energy from a sunrise or sunset into a storage media and applying said storage media to an affected area of a patient to achieve a desired result.

Abstract: A method of treatment of chlamydia trachomatis, Herpes family viral infections and other medical conditions through the removal of localized heavy metal (eg. Hg) and/or Al deposits and delivering antibiotics and/or antiviral agents along with the ingestion of greens taken from the Umbelliferae family of vegetables including leaves of Coriandrum Sativum known as cilantro or Chinese parsley coupled with drug intake enhancement methods.

Abstract: A human IgG.sub.1 type monoclonal antibody which possesses a molecular weight in the range of 180,000.+-.20,000 as measured by the method of polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulfate and is specific to nicotinic acetylcholine receptor. The human IgG.sub.1 type monoclonal antibody mentioned above is produced by a method which comprises fusing human cells capable of producing an antibody against nicotinic acetylcholine receptor with propagable human cells thereby giving rise to a hybridoma capable of producing the aforementioned human IgG.sub.1 type monoclonal antibody, selecting the hybridoma from the production of the fusion, culturing the hybridoma thereby giving rise to the aforementioned human IgG.sub.1 type monoclonal antibody, and selecting the antibody from the cultured medium. The hybridoma mentioned above is also identified.

Abstract: A method of imaging an internal organ of a patient for purposes of medical diagnosis, where a patient forms an O-ring shape with one of hands by placing the fingertips of his thumb and one of his remaining fingers together and a sample of tissue of an internal organ is placed on the patient's other hand, and the patient's internal organ is non-invasively externally probed with a probing instrument. The internal organ is the same type of organ as that of the sample.

Abstract: There is disclosed an adsorbent, comprising a carrier on which is immobilized a peptide possessing an ability to bind to the human antibody to the nicotinic acetylcholine receptor and represented by the formula:H--X--A--Y--Zwherein A stands for a peptide residue, one of X and Y stands for a single bond, an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR1## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and the other of X and Y stands for an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR2## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and Z stand

Abstract: A monoclonal anti-idiotypic antibody specific to a human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor; a method for the production of the aforementioned monoclonal anti-idiotypic antibody by the steps of immunizing an animal with a human IgG.sub.1 type monoclonal antibody specific to nicotinic acetylcholine receptor, collecting antibody-producing cells from the animal, fusing the collected cells with neoplastic cells, selecting from the product of fusion a hybridoma capable of producing a monoclonal anti-idiotypic antibody specific to the human IgG.sub.1 type monoclonal antibody possessing specificity to nicotinic acetylcholine receptor, propagating the selected hybridoma thereby giving rise to said monoclonal anti-idiotypic antibody, and collecting the produced monoclonal anti-idiotypic antibody; and use of the monoclonal anti-idiotypic antibody as a reagent and as an adsorbent.

Abstract: A peptide is disclosed which is represented by the formula:H-X-Gly-Trp-Lys-His-Trp-Val-Tyr-Tyr-Thr-Cys-Cys-Pro-Asp-Thr-Pro-Tyr-Leu-Asp -Y -Zwherein one of X and Y stands for a single bond, an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR1## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above, the other of X and Y stands for an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR2## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and Z stands for a hydroxyl group or an amino group, and two cysteinyl mercapto groups in the Cys-Cys moiety may be interlinked to

Abstract: A dynamometer comprising a first member, a second member which is movable relative to the first member along a predetermined path, a piston and cylinder arrangement for resisting movement of the second member with respect to the first member in one direction along the predetermined path with a force which increases from zero with the distance moved from a rest position, and a potentiometer having a first elongate resistor element having two ends and a second wiper element which is in electrical contact with the resistor element and is movable with respect thereto to establish an electrical resistance between the wiper element and one end of the resistor element which increases with relative movement of the elements in one direction.

Abstract: A device for non-invasively monitoring blood flow comprising a support member having a base surface for engaging the skin, and a light source and a light detector which are supported by the support member above the base surface thereof. The light source emits a beam of light in the form of a cone of relatively small angle, and the light detector receives light directed there towards within a collection cone of relatively large angle. The axis of the light beam crosses the axis of the collection cone below the base surface.

Abstract: This type of electrophotography is practiced using a device comprising a holder, a photographic film mounted in the holder, and a light-tight sleeve connected to the holder to enable an object to be placed in contact with the film. An electrode is disposed inside the holder on the opposite side of the film from the object under investigation. A pulse generator capable of producing high voltage pulses having a high-frequency component is connected to the electrode.

Abstract: Novel pesticidal compositions are comprised of a 2,2-dimethyl-3-(substituted ethyl)cyclopropanecarboxylic acid ester as the active ingredient, said cyclopropanecarboxylate having the structural formula: ##STR1## wherein X, Y and Z are the same or different and at least two of same are chlorine or bromine, with the remaining one being hydrogen, methyl, chlorine or bromine; R is an alcohol residue represented by one of the following structural formulae (II), (III), (IV) and (V): ##STR2## where A represents hydrogen, cyano, ethynyl or thiocarbamoyl; Q is hydrogen, chlorine, bromine, fluorine, methyl or trifluoromethyl; R.sup.1 is propargyl or benzyl; R.sup.2 represents 2-halogeno-3-phenyl-1-propen-1-yl, (dihalogenovinyloxy)phenyl, benzylphenyl, phthalimido, thiophthalimido, di- or tetrahydrophthalimido or dialkylmaleimido; R.sup.3 represents allyl, 2,4-pentadienyl, propargyl or benzyl.

Abstract: A geranylgeranylacetamide compound having a piperazine ring represented by the following formula (I) ##STR1## wherein R represents a member selected from the class consisting of a hydrogen atom, C.sub.1 -C.sub.5 alkyl groups which are unsubstituted or mono-substituted by a halogen atom, C.sub.2 -C.sub.5 alkenyl groups and C.sub.7 -C.sub.8 aralkyl groups, R.sub.1 represents a C.sub.1 -C.sub.3 alkyl group, and n represents 0, 1 or 2,and a pharmaceutically acceptable acid addition salt thereof. The aforesaid compound can be prepared by reacting geranylgeranylacetic acid or its reactive derivative with a piperazine compound, and thereafter, if desired, transforming the free geranylgeranylacetamide compound thus obtained into its pharmaceutically acceptable acid addition salt. A pharmaceutical composition containing said compound exhibits antiulcerogenic activity, particularly excellent antipeptic ulcerogenic activity, and is useful as an agent for treating ulcers.

Abstract: Novel insecticidal compositions are comprised of an active isovalerate having the structural formula: ##STR1## wherein Z.sup.1 is hydrogen, ##STR2## Z.sup.2 is either ##STR3## when Z.sup.1 is hydrogen, or hydrogen when Z.sup.1 is either ##STR4## A, when Z.sup.1 is ##STR5## is cyano or ethynyl or, when Z.sup.1 is other than ##STR6## is hydrogen, cyano or ethynyl; X and Y which may be the same or different are chlorine or bromine.

Abstract: Novel pesticidal compositions are comprised of a 2,2-dimethyl-3-(substituted ethyl)cyclopropanecarboxylic acid ester as the active ingredient, said cyclopropanecarboxylate having the structural formula: ##STR1## wherein X, Y and Z are the same or different and at least two of same are chlorine or bromine, with the remaining one being hydrogen, methyl, chlorine or bromine; R is an alcohol residue represented by one of the following structural formulae (II), (III), (IV) and (V): ##STR2## where A represents hydrogen, cyano, ethynyl or thiocarbamoyl; Q is hydrogen, chlorine, bromine, fluorine, methyl or trifluoromethyl; R.sup.1 is propargyl or benzyl; R.sup.2 represents 2-halogeno-3-phenyl-1-propen-1-yl, (dihalogenovinyloxy)phenyl, benzylphenyl, phthalimido, thiophthalimido, di- or tetrahydrophthalimido or dialkylmaleimido; R.sup.3 represents allyl, 2,4-pentadienyl, propargyl or benzyl.

Abstract: A new pyrethroid compound which is low in toxicity to fish and a pesticidal composition containing the same as an active ingredient are provided. The above pyrethroid compound is a substituted cyclopropanecarboxylic acid ester of the general formula: ##STR1## (wherein A is a hydrogen atom or an ethynyl group) Despite its broad pesticidal spectrum and high pesticidal activity, this ester is very low in toxicity to man and domestic animals and especially low in toxicity to fish as compared with the conventional pyrethroid compounds.

Abstract: 1,1,1-Trihalogeno-4-methyl pentenes and 1,1-dihalogeno-4-methyl-1,3-pentadienes are produced. These compounds are of value as intermediates for the production of pyrethrin analogs which are of use as insecticides or agricultural chemicals.